Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Considerations affecting selection of thrombolytic agents.

T C Smitherman1

  • 1Division of Cardiology, 3498 Presbyterian University Hospital, University of Pittsburgh Medical Center, PA 15213.

Molecular Biology & Medicine
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of hostility on platelet reactivity to psychological stress in coronary heart disease patients and in healthy controls.

Psychosomatic medicine·1996
Same author

Analysis of thallium-201 single-photon emission computed tomography after intravenous dipyridamole using different quantitative measures of coronary stenosis severity and receiver operator characteristic curves.

American heart journal·1992
Same author

Direct coronary vasodilation induced by intracoronary vasoactive intestinal peptide.

Journal of cardiovascular pharmacology·1990
Same author

Reverse redistribution of thallium-201 detected by SPECT imaging after dipyridamole in angina pectoris.

The American journal of cardiology·1990
Same author

Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans.

The American journal of physiology·1989
Same author

Comparison of dipyridamole-Doppler echocardiography to thallium-201 imaging and quantitative coronary arteriography in the assessment of coronary artery disease.

The American journal of cardiology·1989

No single ideal thrombolytic regimen exists for acute myocardial infarction. Treatment choice depends on factors like cost, administration time, bleeding risk, and prior drug exposure, guiding selection among streptokinase, anistreplase, and alteplase.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombotic Disease Management

Background:

  • The optimal thrombolytic or combination thrombolytic and anticoagulant regimen for acute myocardial infarction (AMI) remains undefined.
  • Clinical outcomes do not consistently favor one regimen over another, necessitating nuanced treatment decisions.
  • Ongoing and planned clinical trials (e.g., ISIS-3, TAPS, GUSTO, TIMI-4) aim to clarify treatment efficacy.

Purpose of the Study:

  • To review current data on thrombolytic and anticoagulant regimens for AMI.
  • To provide guidance on selecting the most appropriate regimen based on specific clinical circumstances and patient factors.
  • To anticipate future advancements in thrombolytic and antithrombotic therapies.

Main Methods:

  • Review of existing data on thrombolytic therapy for AMI.

Related Experiment Videos

  • Comparative analysis of different thrombolytic agents (streptokinase, anistreplase, alteplase) and anticoagulant strategies.
  • Consideration of factors influencing regimen choice, including economics, administration logistics, patient history, and bleeding risk.

    • Main Results:

    • Streptokinase may be preferred in resource-limited settings due to cost-effectiveness.
    • Anistreplase offers ease of administration for early, pre-hospital interventions.
    • Alteplase may be favored when bleeding risk is a concern (excluding intracranial) or for later treatment initiation (>3 hours post-infarction).
    • Contraindications include recent use of streptokinase/anistreplase or streptococcal infection.
    • Streptokinase may be preferred when intracranial hemorrhage risk is heightened.

    Conclusions:

    • The choice of thrombolytic regimen requires careful consideration of individual patient factors and clinical context.
    • Economic factors, administration feasibility, bleeding risk, and prior drug exposure influence optimal agent selection.
    • Timely administration of effective thrombolytic therapy is paramount, regardless of regimen debates; future therapies will likely involve combination agents and novel drug classes.